Group 1 - The core point of the article is that Beida Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange [2] - The joint sponsors for the listing are Morgan Stanley and CITIC Securities [2]

Core Viewpoint - Beida Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, marking its third attempt to go public in Hong Kong after two unsuccessful attempts in 2021 [1][4]. Group 1: Company Overview - Beida Pharmaceutical is a pioneer in China's innovative drug research and development industry, successfully transforming from a biotech company focused on innovative drug discovery to a leading and profitable biopharmaceutical company [4]. - The company has established an integrated platform driven by four core pillars: mature commercialization capabilities, comprehensive drug discovery and development capabilities, forward-looking business development layout, and a competitive innovation ecosystem [4]. Group 2: Product Pipeline and Market Position - Beida Pharmaceutical has launched eight commercialized products, including five innovative drugs and one biosimilar, achieving several "firsts" in China [5]. - The company has built a comprehensive drug pipeline targeting key lung cancer pathways, including EGFR and ALK, and is expanding into high-potential treatment areas such as breast cancer, kidney cancer, hematology, and ophthalmology [4][5]. Group 3: Financial Performance - For the fiscal years ending December 31, 2022, 2023, 2024, and the six months ending June 30, 2025, Beida Pharmaceutical reported revenues of approximately RMB 2.377 billion, RMB 2.456 billion, RMB 2.892 billion, and RMB 1.731 billion respectively [5][7]. - The annual profits for the same periods were approximately RMB 125 million, RMB 334 million, RMB 387 million, and RMB 131 million respectively [5][7].

据港交所9月29日披露，贝达药业股份有限公司(简称：贝达药业(300558.SZ))向港交所主板提交上市申请书，联席保荐人为摩根士丹利、中信证 券。值得注意的是，这已是贝达药业第三次启动港股上市计划。回溯2021年，公司曾于2月、12月两度向香港联合交易所递交招股书，但两次上 市尝试均未成功。 招股书显示，贝达药业是中国创新药研发行业的先行者与引领者，从专注创新药发现与研发的生物科技公司成功转型为行业领先、盈利良好的 生物制药公司。公司已打造自主研发、市场拓展、战略合作与生态圈建设"四驾马车"协同驱动的一体化平台，公司至今已成功推出八款商业化 产品，其中多项产品实现"中国首个"突破。自2011年首款产品上市当年起，公司连续多年实现盈利，稳居中国创新药企前列。 自2003年成立以来，公司始终致力于研发用于治疗肿瘤的新型药物，以应对肺癌及其他主要癌症领域中亟待解决的临床需求。一方面，通过自 主研发与战略合作相结合的模式，公司构建了涵盖关键肺癌靶点（包括表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK））的全面药 物管线，这有助于公司在创新靶向肺癌治疗领域确立领先地位。另一方面，公司不断拓展至高潜力治疗领域， ...

Core Viewpoint - Beida Pharmaceutical has submitted its third listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CITIC Securities as joint sponsors, following two unsuccessful attempts in 2021 [1][4]. Company Overview - Beida Pharmaceutical is a pioneer in China's innovative drug research and development industry, successfully transforming from a biotech company focused on innovative drug discovery to a leading and profitable biopharmaceutical company [4][5]. - The company has established an integrated platform driven by four core pillars: independent research and development, market expansion, strategic cooperation, and ecosystem construction [4]. Product Pipeline - Beida has launched eight commercialized products, including five innovative drugs and one biosimilar, with a comprehensive pipeline covering key lung cancer targets and expanding into other high-potential treatment areas such as breast cancer, kidney cancer, hematology, and ophthalmology [5][4]. Financial Performance - The company reported revenues of approximately RMB 2.377 billion, RMB 2.456 billion, RMB 2.892 billion, and RMB 1.731 billion for the fiscal years 2022, 2023, 2024, and the first half of 2025, respectively [5][7]. - Net profits for the same periods were approximately RMB 125 million, RMB 334 million, RMB 387 million, and RMB 131 million [5][7].

Group 1 - Sichuan Baili Tianheng Pharmaceutical Co., Ltd., WeDoctor Holdings Limited, Betta Pharmaceuticals Co., Ltd., Dajin Heavy Industry Co., Ltd., and LEO Group Co., Ltd. submitted listing applications to the Hong Kong Stock Exchange on September 29, aiming for a main board listing [1]. Group 2 - The companies are seeking to raise capital through the issuance of H-shares, with each H-share having a par value of RMB 1.00 [4][10][16]. - The underwriting process involves several joint sponsors, including Goldman Sachs, J.P. Morgan, Morgan Stanley, and CITIC Securities, among others [4][10][12].

证券代码：300558 证券简称：贝达药业 公告编号：2025-066 贝达药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形； 2、本次股东大会没有涉及变更前次股东大会决议。 一、会议召开和出席情况 贝达药业股份有限公司（以下简称"公司"）2025 年第一次临时股东大会会 议通知于 2025 年 9 月 10 日以公告形式发出，现场会议于 2025 年 9 月 26 日（星 期五）14:30 在公司行政大楼一楼会议室召开，通过深圳证券交易所交易系统进 行网络投票的具体时间为 2025 年 9 月 26 日的交易时间，即 9:15-9:25、9:30-11:30、 13:00-15:00；通过深圳证券交易所互联网投票系统进行投票的具体时间为 2025 年 9 月 26 日 9:15-15:00 期间的任意时间。 本次股东大会采取现场投票和网络投票相结合的方式召开。通过现场和网络 投票的股东及股东授权委托代表 286 人，代表股份 199,299,693 股 ...

国浩律师（杭州）事务所 贝达药业 2025 年第一次临时股东大会法律意见书 国浩律师（杭州）事务所 关于 贝达药业股份有限公司 2025 年第一次临时股东大会 的 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二五年九月 国浩律师（杭州）事务所 贝达药业 2025 年第一次临时股东大会法律意见书 国浩律师（杭州）事务所 关于 贝达药业股份有限公司 2025 年第一次临时股东大会的法律意见书 致：贝达药业股份有限公司 国浩律师（杭州）事务所（以下简称本所）接受贝达药业股份有限公司（以 下简 ...

Core Viewpoint - The article discusses the challenges faced by Betta Pharmaceuticals, particularly the decline in profitability and the impact of product competition on its financial health, leading to a liquidity crisis and the need for a third attempt at an IPO in Hong Kong [6][14]. Financial Performance - In the first half of 2025, Betta Pharmaceuticals reported a revenue of 1.731 billion yuan, a year-on-year increase of 15.37%, but the net profit dropped by 37.53% to 140 million yuan, indicating a dangerous trend of "increased revenue without increased profit" [7][10]. - The second quarter of 2025 saw a significant decline in profitability, with a revenue of 814 million yuan corresponding to a net profit of 39.808 million yuan, a staggering year-on-year decrease of 68.36% [7][10]. Product Challenges - The core product, Camrelizumab (凯美纳), has seen a cumulative price drop of 54% due to multiple rounds of medical insurance negotiations and is facing competition from generics after its patent expiration in 2023, leading to stagnation in growth [6][8]. - Another key product, Ensartinib (贝美纳), is under pressure with a 71% price reduction and competition from five similar products in the European market, resulting in declining gross margins [8][9]. - The third-generation EGFR inhibitor, Bafetinib (贝福替尼), has not met sales expectations, with first-half sales failing to reach the disclosure threshold of 173 million yuan, significantly below the market expectation of 1 billion yuan [8][9]. Research and Development (R&D) Issues - Betta Pharmaceuticals has reduced its R&D investment from 700 million yuan in 2022 to 500 million yuan in 2024, with only 226 million yuan spent in the first half of 2025, a year-on-year decrease of 10.4% [9][15]. - The R&D team size has halved from 647 to 327, contrasting sharply with the industry trend where A-share innovative pharmaceutical companies increased R&D investment by 18% in the same period [9][15]. Cash Flow and Debt Situation - The company's operating cash flow has deteriorated, with a net cash flow from operating activities of 445 million yuan in the first half of 2025, a decline of 14.7% year-on-year [10][11]. - As of June 2025, current liabilities exceeded current assets by 398 million yuan, resulting in a current ratio of only 0.77, indicating significant short-term debt repayment pressure [10][11]. IPO Attempts and Market Conditions - Betta Pharmaceuticals announced its third attempt at an IPO in September 2025, aiming to issue up to 15% of its total shares, with the primary goal of alleviating liquidity issues [14][16]. - The previous two IPO attempts in 2021 were unsuccessful due to deteriorating financial conditions and market sentiment, with the second application expiring in June 2022 [13][14]. Industry Context - The challenges faced by Betta Pharmaceuticals reflect broader issues within the Chinese innovative pharmaceutical sector, including price controls, intensified competition, and a decline in new drug applications [14][15]. - The article highlights the need for companies to adapt by focusing on new global targets and improving cost control to survive in a competitive landscape [15][16].

Core Viewpoint - Bidda Pharmaceutical is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and competitiveness, while also advancing its internationalization process [1] Group 1: Financial Performance - For the first half of 2025, Bidda Pharmaceutical reported revenue of 1.731 billion yuan, a year-on-year increase of 15.37%, but the net profit attributable to shareholders dropped by 37.53% to 140 million yuan, marking the first half-year profit decline since 2022 [2] - The company's second-quarter performance showed a revenue of 814 million yuan, a slight increase of 6.39%, while net profit fell significantly by 68.36% to 39.81 million yuan [2] Group 2: Debt and Financial Pressure - Bidda Pharmaceutical is facing financial pressure, with current assets of 1.359 billion yuan against current liabilities of 1.757 billion yuan as of mid-2023, resulting in a cash and cash equivalents balance of 527 million yuan [4] - The company has an outstanding payment of 180 million yuan to Yifang Bio for a milestone payment related to a lung cancer drug project, which has been overdue for nearly two years [3] - As of the first half of 2025, the total accounts payable amounted to 580 million yuan, with 180 million yuan being overdue payments to Yifang Bio [3] Group 3: Research and Development - Bidda Pharmaceutical's R&D investment has been declining, dropping from 700 million yuan in 2022 to 500 million yuan in 2024, with only 255 million yuan spent in the first half of 2025, a slight decrease of 0.63% year-on-year [3]

Core Viewpoint - Betta Pharmaceuticals is making a third attempt to list on the Hong Kong Stock Exchange (HKEX) after two previous unsuccessful attempts in 2021, raising questions about its ability to pass HKEX scrutiny and achieve its listing goals [1][2]. Group 1: Company Overview - Betta Pharmaceuticals focuses on innovative drug research and development, integrating R&D, production, and marketing [2]. - The company has eight marketed products targeting various cancers, including lung, kidney, and breast cancer [2]. - Betta Pharmaceuticals was listed on the Shenzhen Stock Exchange in 2016 [2]. Group 2: Financial Performance - In the first half of 2025, Betta Pharmaceuticals reported a revenue of 1.731 billion yuan, a year-on-year increase of 15.37%, but net profit fell by 37.53% to 140 million yuan [2][3]. - The second quarter of 2025 saw a significant net profit decline of 68.36%, marking the first instance of a year-on-year decrease in net profit since 2023 [2]. Group 3: Cost Structure - The decline in net profit is attributed to increased depreciation and amortization expenses [3]. - R&D expenses decreased by 10.40% to 226 million yuan, while sales expenses rose by 13.34% to 594 million yuan [3]. Group 4: Financial Pressure - As of June 30, 2025, Betta Pharmaceuticals had current assets of 1.359 billion yuan, which is lower than current liabilities of 1.757 billion yuan, indicating short-term solvency issues [4]. - The net cash flow from operating activities was 445 million yuan, a decrease of 14.70% year-on-year, highlighting liquidity challenges [4]. Group 5: Debt Issues - Betta Pharmaceuticals has an outstanding payment of 180 million yuan to Yifang Bio for a collaboration agreement, with some payments overdue for over two years [4][5]. - The company has marked the reason for the unpaid amount as "not yet settled," indicating ongoing disputes [5]. Group 6: Product Dependency - The company's net profit margin dropped to 7.55%, down from 14.40% in the previous year, largely due to high dependency on core products and a lack of new product support [6]. - The main revenue drivers are two products, Kai Mei Na and Bei Mei Na, which have historically contributed significantly to revenue [6]. Group 7: Market Competition - The third-generation EGFR inhibitor, Sai Mei Na, has not performed as expected in the market, with sales failing to meet the threshold of 10% of total revenue [7]. - New products like Kang Mei Na and Ao Fu Min face stiff competition from established players, limiting their potential revenue contributions [8]. Group 8: Future Outlook - The company aims to use the funds raised from the IPO for R&D, potential acquisitions, and expanding its marketing network [5]. - The ability of Betta Pharmaceuticals to navigate current challenges and achieve its IPO goals remains a focal point for market observers [8].